Axon Enterprise (NASDAQ:AXON) Stock Price Up 6.4% – Time to Buy?

Posted by Geri Gentry on Sep 16th, 2026

Shares of Axon Enterprise, Inc (NASDAQ:AXON – Get Free Report) traded up 6.4% during trading on Wednesday . The company traded as high as $467.97 and last traded at $470.4250. Approximately 1,463,181 shares changed hands during mid-day trading, an increase of 39% from the average session volume of 1,050,970 shares. The stock had previously closed at $442.08.

Key Headlines Impacting Axon Enterprise

Here are the key news stories impacting Axon Enterprise this week:

Positive Sentiment: Axon priced $1 billion of 0% convertible senior notes due 2031, with underwriters able to purchase an additional $150 million. The notes carry no cash interest, allowing Axon to raise capital at a low stated financing cost and potentially strengthen its balance sheet for acquisitions, product development and expansion of its public-safety software platform. Axon Announces Pricing of Convertible Notes
Neutral Sentiment: Analysts and investors remain divided: Axon’s recurring software revenue, connected devices and law-enforcement technology are viewed as strengthening its competitive moat, but commentary emphasizes that the stock’s margin of safety is limited after its premium valuation. Recent quarterly revenue rose 35.3% year over year and exceeded estimates, although earnings declined from the prior-year period. Axon Enterprise Valuation Analysis
Negative Sentiment: The offering triggered a selloff because convertible notes can ultimately be exchanged for shares, creating potential dilution and an overhang on the stock. Investors also questioned why Axon needed to raise substantial capital, with reports pointing to pressure on cash flow and a desire to replenish its “war chest.” What’s Going On With Axon Shares
Negative Sentiment: Axon’s elevated earnings multiple makes the stock particularly sensitive to financing and dilution concerns. A reported insider sale of 1,017 shares worth approximately $489,000 added a modest negative signal, although the transaction was executed under a pre-arranged Rule 10b5-1 plan and represents only a small reduction in the insider’s holdings. Axon Insider Sale

Analyst Ratings Changes

A number of brokerages recently commented on AXON. The Goldman Sachs Group restated a “buy” rating and issued a $715.00 target price on shares of Axon Enterprise in a research note on Thursday, August 6th. Barclays boosted their price target on shares of Axon Enterprise from $523.00 to $688.00 and gave the company an “overweight” rating in a report on Thursday, August 6th. Needham & Company LLC restated a “buy” rating on shares of Axon Enterprise in a research note on Wednesday, September 2nd. UBS Group lifted their target price on shares of Axon Enterprise from $440.00 to $600.00 and gave the company a “neutral” rating in a research report on Thursday, August 6th. Finally, Weiss Ratings reissued a “hold (c-)” rating on shares of Axon Enterprise in a research note on Wednesday, August 5th. Fourteen equities research analysts have rated the stock with a Buy rating and three have assigned a Hold rating to the company’s stock. Based on data from MarketBeat, Axon Enterprise currently has a consensus rating of “Moderate Buy” and an average price target of $721.57.

Get Our Latest Research Report on AXON

Axon Enterprise Stock Performance

The company has a quick ratio of 1.80, a current ratio of 2.15 and a debt-to-equity ratio of 0.47. The stock has a fifty day simple moving average of $555.06 and a 200-day simple moving average of $488.60. The company has a market capitalization of $37.80 billion, a P/E ratio of 193.24, a PEG ratio of 9.23 and a beta of 1.40.

Axon Enterprise (NASDAQ:AXON – Get Free Report) last posted its earnings results on Wednesday, August 5th. The biotechnology company reported $1.88 earnings per share for the quarter, topping the consensus estimate of $1.84 by $0.04. The business had revenue of $904.39 million for the quarter, compared to analyst estimates of $876.42 million. Axon Enterprise had a net margin of 6.19% and a return on equity of 2.84%. The firm’s quarterly revenue was up 35.3% compared to the same quarter last year. During the same quarter in the prior year, the firm earned $2.12 EPS. Equities analysts forecast that Axon Enterprise, Inc will post 2.12 EPS for the current year.

Insider Activity

In related news, insider Jeffrey C. Kunins sold 9,605 shares of the stock in a transaction that occurred on Friday, August 21st. The stock was sold at an average price of $626.70, for a total transaction of $6,019,453.50. Following the sale, the insider directly owned 97,761 shares in the company, valued at $61,266,818.70. This represents a 8.95% decrease in their position. The transaction was disclosed in a legal filing with the Securities & Exchange Commission, which is available at the SEC website. The transaction was executed under a pre-arranged Rule 10b5-1 trading plan. Also, CEO Patrick W. Smith sold 10,000 shares of the firm’s stock in a transaction on Tuesday, September 8th. The shares were sold at an average price of $508.99, for a total value of $5,089,900.00. Following the sale, the chief executive officer directly owned 3,118,012 shares of the company’s stock, valued at $1,587,036,927.88. This represents a 0.32% decrease in their ownership of the stock. The disclosure for this sale is available in the SEC filing. The transaction was executed under a pre-arranged Rule 10b5-1 trading plan. Insiders sold a total of 67,397 shares of company stock valued at $38,160,884 over the last three months. 4.20% of the stock is owned by corporate insiders.

Institutional Trading of Axon Enterprise

Several large investors have recently made changes to their positions in the business. Creative Financial Designs Inc. ADV acquired a new stake in Axon Enterprise during the 4th quarter valued at $28,000. Keating Financial Advisory Services Inc. acquired a new position in shares of Axon Enterprise in the second quarter valued at $31,000. Washington Trust Advisors Inc. raised its position in shares of Axon Enterprise by 1,300.0% in the second quarter. Washington Trust Advisors Inc. now owns 70 shares of the biotechnology company’s stock valued at $39,000 after purchasing an additional 65 shares during the period. Delos Wealth Advisors LLC acquired a new stake in shares of Axon Enterprise during the 2nd quarter worth about $45,000. Finally, Owl Creek Wealth Partners LLC lifted its stake in shares of Axon Enterprise by 84.8% during the 2nd quarter. Owl Creek Wealth Partners LLC now owns 85 shares of the biotechnology company’s stock worth $48,000 after buying an additional 39 shares during the last quarter. Institutional investors own 79.08% of the company’s stock.

About Axon Enterprise

(Get Free Report)

Axon Enterprise, Inc develops technology and equipment for law enforcement, public safety and other government agencies. Its product portfolio includes TASER energy weapons, body-worn cameras, in-car cameras and related connected devices designed to support safer interactions, improve transparency and collect operational data.

The company also provides cloud-based software for managing digital evidence, conducting investigations, overseeing records and workflows, coordinating dispatch and supporting real-time public safety operations.